Search results for "Hepadnavirus"

showing 10 items of 19 documents

HBV-DNA suppression and disease course in HBV cirrhosis patients on long-term lamivudine therapy

2005

In hepatitis B virus (HBV) cirrhosis patients on long-term lamivudine (LAM), the relationships between HBV suppression, development of viral resistance and disease outcome are unclear. We analysed the dynamic of serum HBV-DNA and its relationship with the clinical course of 59 patients (52 males, mean age 51.4 ±8.4 years, 12 HBeAg positive and 47 HBeAg negative, and 57 genotype D and two genotype A) with cirrhosis (45 in Child-Turcotte-Pugh class A) and high levels of serum HBV-DNA (median 14.7x107 genomes/ml) treated with LAM [median (range): 44 (15–78) months]. A total of 50 patients (84.7%) achieved a virological response (serum HBV-DNA negative by PCR) during the first 6 months of ther…

AdultLiver CirrhosisMaleHepatitis B virusCirrhosisHBV DNA Lamivudine Therapy suppression HBV diseasemedicine.disease_causeVirus ReplicationAntiviral AgentsVirusDrug Administration ScheduleDisease courseCohort StudiesOrthohepadnavirusmedicineHumansPharmacology (medical)AgedPharmacologyHepatitis B virusbiologyReverse-transcriptase inhibitorLamivudineMiddle Agedbiology.organism_classificationmedicine.diseaseHepatitis BVirologydigestive system diseasesInfectious DiseasesHepadnaviridaeLamivudineDNA ViralMutationFemalemedicine.drug
researchProduct

Can the serological status of anti-HBc alone be considered a sentinel marker for detection of occult HBV infection?

2008

Some individuals have “occult” infection with hepatitis B virus (HBV), defined as presence of HBV genome in the serum or liver tissue without HBV surface antigen (HBsAg) in the serum. The aim of this study was to investigate whether serum antibodies against HBV core antigen in isolation (“anti-HBc alone”) are a useful marker of “occult” HBV in patients with or without hepatitis C virus (HCV) infection. “Anti-HBc alone” was detected in the sera of 119/6,544 (1.8%) asymptomatic outpatients referred to the diagnostic laboratory for routine testing for viral hepatitis, 62/607 (10.2%) drug users, and 42/195 (21.5%) patients with hepatocellular carcinoma. Using three in-house nested-PCR amplifica…

AdultMaleHBV serologic markerHBsAgHepatitis B virusGenotypeHepatitis C virusHBV genotypemedicine.disease_causeSettore MED/42 - Igiene Generale E ApplicataPolymerase Chain ReactionSensitivity and Specificity‘‘occult’’ HBVSerologyOrthohepadnavirusVirologymedicinePrevalenceHumansSerologic TestsHCCAgedHepatitis B virusAged 80 and overbiologybusiness.industryvirus diseasesSequence Analysis DNAHepatitis C AntibodiesMiddle Agedbiology.organism_classificationmedicine.diseaseHepatitis BVirologyHepatitis B Core AntigensHepatitis Cdigestive system diseasesInfectious DiseasesHepadnaviridaeImmunologyDNA Viralanti-HBcFemaleViral diseasebusinessViral hepatitisSentinel Surveillance
researchProduct

Virological profiles in patients with chronic hepatitis C and overt or occult HBV infection

2002

Abstract OBJECTIVES: The virological profiles of hepatitis B and C viruses (HBV and HCV) and their interplay in cases of coinfection are undefined. A suppressed and occult HBV infection may occur in hepatitis B surface antigen (HBsAg) negative patients with chronic hepatitis C. The HCV core protein is able to inhibit HBV “in vitro,” and serines at positions 99 and 116 are essential for such inhibition. We aimed to assess the HBV and HCV virological profiles in cases of coinfection and to evaluate the relationship between HCV core gene variability and HBV activity. METHODS: Eighty-two anti-HCV positive patients were examined: 35 cases were HBsAg positive, 24 were HBsAg negative with “occult”…

AdultMaleHepatitis B virusHBsAgHCV RNAHepacivirusHepatitis C virusDUAL INFECTION; INTERFERON THERAPY; HEPATOCELLULAR-CARCINOMA; CHRONIC LIVER-DISEASE; HCV core protein; Hepatitis B Surface Antigens; HCV RNAGenome ViralHepacivirusDUAL INFECTIONVirus Replicationmedicine.disease_causeCHRONIC LIVER-DISEASEHepatitis B ChronicINTERFERON THERAPYOrthohepadnavirusHEPATOCELLULAR-CARCINOMAmedicineHumansAgedHepatitis B virusHepatitis B Surface AntigensHepatologybiologybusiness.industryHCV core proteinGastroenterologyvirus diseasesHepatitis C ChronicMiddle AgedViral LoadHepatitis Bbiology.organism_classificationmedicine.diseaseVirologydigestive system diseasesHepadnaviridaeDNA ViralImmunologyCoinfectionRNA ViralFemalebusinessThe American Journal of Gastroenterology
researchProduct

Occult hepatitis B virus in liver tissue of individuals without hepatic disease

2008

Abstract BACKGROUND/AIMS: While many data are available concerning occult hepatitis B virus (HBV) infection in patients with hepatic disorders, there is little information about this cryptic infection in individuals without liver disease. The aim of this study was to investigate the prevalence of occult HBV in the general population by examining liver specimens from a large series of HBV-surface-antigen negative individuals with no clinical and biochemical evidence of liver disease. METHODS: The presence of HBV DNA was evaluated by testing, through polymerase chain reaction techniques, DNA extracts from 98 liver-disease-free individuals who underwent liver resection or needle biopsy during …

AdultMaleHepatitis B virusHBsAgHepatitis C virusPopulationhepatitis B virus liver tissuemedicine.disease_causeLiver diseaseNormal liverOrthohepadnavirusOccult HBVOccult HBV; HBV DNA; Normal liver; Anti-HBc; HBV-seronegativemedicineHumansHBV-seronegativeHepatitis B AntibodieseducationAgedHepatitis B viruseducation.field_of_studyHepatologybiologybusiness.industryvirus diseasesMiddle AgedHepatitis Bmedicine.diseasebiology.organism_classificationHepatitis B Core AntigensOccultdigestive system diseasesLiverHepadnaviridaeHBV DNACarrier StateDNA ViralImmunologyFemalebusinessAnti-HBcJournal of Hepatology
researchProduct

Variability of reverse transcriptase and overlapping S gene in hepatitis B virus isolates from untreated and lamivudine-resistant chronic hepatitis B…

2009

Background The high degree of diversity of the hepatitis B virus (HBV) quasispecies in chronically infected individuals raises the possibility that HBV genetic variants favouring resistance to nucleoside/nucleotide analogues (NAs) might pre-exist to treatment. The aim of this study was to investigate the genetic variability of the entire HBV reverse transcriptase (RT) domain and of the overlapping S gene in a large series of untreated hepatitis B surface antigen carriers and in lamivudine (3TC)-resistant patients. Methods Sequencing analysis of the entire HBV RT domain of isolates from 100 untreated (treatment- naive group) and 59 3TC-resistant (3TC-resistant group) consecutive patients wit…

AdultMaleSettore MED/07 - Microbiologia E Microbiologia ClinicaHepatitis B virusAdult; Aged; Drug Resistance; Viral; Female; Genetic Variation; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B; Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; RNA-Directed DNA Polymerase; Reverse Transcriptase Inhibitors; Sequence Analysis; DNA; Treatment OutcomeDrug ResistanceViral quasispeciesmedicine.disease_causeVirusHepatitis B ChronicOrthohepadnavirusDrug Resistance ViralmedicineHumansPharmacology (medical)ViralChronicAgedPharmacologyHepatitis B virusSettore MED/12 - GastroenterologiaHepatitis B Surface AntigensbiologyReverse-transcriptase inhibitorLamivudineGenetic VariationRNA-Directed DNA PolymeraseSequence Analysis DNADNAMiddle Agedbiology.organism_classificationHepatitis BVirologyReverse transcriptaseInfectious DiseasesTreatment OutcomeHepadnaviridaeLamivudineMutationReverse Transcriptase InhibitorsHBV reverse transcriptase gene S lamivudine resistantFemaleSequence Analysismedicine.drug
researchProduct

Assessment of determinants affecting the dual topology of hepadnaviral large envelope proteins

2004

For functional diversity, the large (L) envelope protein of hepatitis B virus (HBV) acquires a dual transmembrane topology via co-translational membrane integration of the S region and partial post-translational translocation of the preS subdomain. Because each process requires the second transmembrane segment (TM2), we explored the action of this determinant by using protease protection analysis of mutant L proteins. We demonstrated that neither the disruption of a leucine zipper-like motif by multiple alanine substitutions nor the flanking charges of TM2 affected the topological reorientation of L. The dispensability of both putative subunit interaction modules argues against a link betwe…

AlanineHepatitis B virusHepatitis B virusVirus AssemblyAmino Acid MotifsMolecular Sequence DataProtein domainPhenotype mixingBiological TransportBiologyEndoplasmic Reticulummedicine.disease_causeVirologyTransmembrane domainDual topologyAmino Acid SubstitutionViral Envelope ProteinsVirologyMembrane topologymedicineHepadnavirusAmino Acid SequenceProtein Processing Post-TranslationalJournal of General Virology
researchProduct

Duck Hepatitis B Virus Requires Cholesterol for Endosomal Escape during Virus Entry

2008

ABSTRACT The identity and functionality of biological membranes are determined by cooperative interaction between their lipid and protein constituents. Cholesterol is an important structural lipid that modulates fluidity of biological membranes favoring the formation of detergent-resistant microdomains. In the present study, we evaluated the functional role of cholesterol and lipid rafts for entry of hepatitis B viruses into hepatocytes. We show that the duck hepatitis B virus (DHBV) attaches predominantly to detergent-soluble domains on the plasma membrane. Cholesterol depletion from host membranes and thus disruption of rafts does not affect DHBV infection. In contrast, depletion of chole…

AvihepadnavirusbiologyvirusesImmunologyDuck hepatitis B virusBiological membraneEndosomesVirus Internalizationbiology.organism_classificationMicrobiologyVirologyVirusHepatitis B Virus DuckVirus-Cell InteractionsCholesterolViral envelopeHepadnaviridaeViral entryCell Line TumorVirologyInsect ScienceHepatocytesHumanslipids (amino acids peptides and proteins)Lipid raftJournal of Virology
researchProduct

HBV-specific immune defect in chronic hepatitis B (CHB) is correlated with a dysregulation of pro- and anti-inflammatory cytokines.

1999

SUMMARY The aim of this study was to examine the immunomodulating effects of rhIL-12 on the immune response induced by hepatitis B virus (HBV) antigens in clinical subgroups of patients with HBV infection. Peripheral blood mononuclear cells (PBMC) of 80 patients were stimulated with HBsAg, HBcAg, pre-S1Ag and tetanus toxoid in the absence or presence of IL-12 (0.01, 0.1 and 1 ng/ml). Stimulation by anti-CD3 + anti-CD28 and lipopolysaccharide (LPS) were used as controls. Proliferation and cytokine production were determined by 3H-thymidine uptake and ELISA after 72 h. After stimulation with HBV antigens only, production of tumour necrosis factor-alpha (TNF-α) or IL-10 was observed in all pat…

HBsAgHepatitis B virusImmunologyAntigen-Presenting CellsIn Vitro Techniquesmedicine.disease_causeLymphocyte ActivationHepatitis B AntigensInterferon-gammaHepatitis B ChronicOrthohepadnavirusmedicineImmunology and AllergyHumansHepatitis B AntibodiesHepatitisHepatitis B virusbiologybusiness.industryTumor Necrosis Factor-alphavirus diseasesOriginal ArticlesHepatitis Bmedicine.diseasebiology.organism_classificationVirologyInterleukin-12digestive system diseasesRecombinant ProteinsInterleukin-10HBcAgHBeAgHepadnaviridaeImmunologyDNA ViralLeukocytes MononuclearCytokinesInflammation MediatorsbusinessClinical and experimental immunology
researchProduct

Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants

2005

The long-term efficacy of hepatitis B vaccine, long-term effectiveness of hepatitis B immunisation programmes, immune memory induced by hepatitis B vaccine, current booster policies, and impact of hepatitis B virus mutants on immunisation programmes were reviewed at the Viral Hepatitis Prevention Board (VHPB) meeting in Sevilla, Spain, March 2004. The main focus was on universal vaccination programmes with data being presented from Italy, Saudi Arabia, Singapore, Spain, Taiwan, Thailand, The Gambia, and USA (Alaska).

Hepatitis B vaccineSettore MED/42 - Igiene Generale e ApplicataImmunization Secondarymedicine.disease_causeTimeOrthohepadnavirusparasitic diseasesHumanshepatitis B vaccination long-term efficacy virus mutantsMedicineHepatitis B VaccinesHepatitis B AntibodiesHepatitis B virusGeneral VeterinaryGeneral Immunology and MicrobiologybiologyImmunization Programsbusiness.industryPublic Health Environmental and Occupational HealthHepatitis BHepatitis Bbiology.organism_classificationmedicine.diseaseVirologyVaccinationInfectious DiseasesHepadnaviridaeDNA ViralMutationMolecular MedicineViral diseasebusinessViral hepatitisImmunologic Memorygeographic locationsVaccine
researchProduct

Mosaic hepatitis B virus core particles presenting the complete preS sequence of the viral envelope on their surface

2004

The sequence of the preS domain of the hepatitis B virus (HBV, genotype D) envelope was inserted into the major immunodominant region (MIR) of the C-terminally truncated HBV core (HBc) protein. In Escherichia coli, the HBc–preS fusion protein was partially soluble and did not produce particles. Co-expression of the wild-type HBc as a helper protein along with the fusion protein led to the formation of mosaic HBc particles that exhibited HBc, preS1 and preS2 antigenicity. Two alternative combinations of medium- and high-copy plasmids were used for co-expression of fusion and helper proteins, in an attempt to improve mosaic particle production. However, the preS fusion content of the particle…

Hepatitis B virusAntigenicityvirusesAntibodies ViralProtein Engineeringmedicine.disease_causeVirusMiceViral Envelope ProteinsOrthohepadnavirusViral envelopeVirologyEscherichia colimedicineAnimalsProtein PrecursorsHepatitis B virusHepatitis B Surface AntigensbiologyViral Core Proteinsvirus diseasesProtein engineeringHepatitis Bbiology.organism_classificationVirologyFusion proteindigestive system diseasesHepadnaviridaeFemaleImmunizationReassortant VirusesPlasmidsJournal of General Virology
researchProduct